Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials

Abstract Introduction Deucravacitinib, a novel, oral, selective allosteric tyrosine kinase 2 inhibitor, demonstrated superiority versus placebo and apremilast in the POETYK PSO-1 and PSO-2 studies. We describe patient-reported outcomes with deucravacitinib treatment versus placebo and apremilast in...

ver descrição completa

Detalhes bibliográficos

Principais autores:	April W. Armstrong, Matthias Augustin, Jennifer L. Beaumont, Tan P. Pham, Stacie Hudgens, Kenneth B. Gordon, Joe Zhuo, Brandon Becker, Yichen Zhong, Renata M. Kisa, Subhashis Banerjee, Kim A. Papp
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Adis, Springer Healthcare 2024-07-01
coleção:	Dermatology and Therapy
Assuntos:	Clinical trial Minimum clinically important difference Psoriasis Quality of life Treatment efficacy
Acesso em linha:	https://doi.org/10.1007/s13555-024-01224-x
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!